Hussam Albassam

Hussam Albassam

Auto-generated profile, based on publicly available information

Hussam Albassam

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
AOAhmad Jomah Obaidullah
Ahmad Jomah Obaidullah
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
HAHussam Albassam
Hussam Albassam
AAAbdulrahman Almehizia
Abdulrahman Almehizia
TETalha Bin Emran
Talha Bin Emran
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in a contagious respiratory tract infection that has become a global burden since the end of 2019. Notably, fewer patients infected with SARS-CoV-2 progress from acute disease onset to death compared with the progression rate associated with two other coronaviruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Several research organizations and pharmaceutical industries have attempted to develop successful vaccine candidates for the prevention of COVID-19. However, increasing evidence indicates that the SARS-CoV-2 genome undergoes frequent mutation; thus, an adequate analysis of the viral strain remains necessary to construct effective vaccines. The current study attempted to design a multi-epitope vaccine by utilizing an approach based on the SARS-CoV-2 structural proteins. We predicted the antigenic T- and B-lymphocyte responses to four structural proteins after screening all structural proteins according to specific characteristics. The predicted epitopes were combined using suitable adjuvants and linkers, and a secondary structure profile indicated that the vaccine shared similar properties with the native protein. Importantly, the molecular docking analysis and molecular dynamics simulations revealed that the constructed vaccine possessed a high affinity for toll-like receptor 4 (TLR4). In addition, multiple descriptors were obtained from the simulation trajectories, including the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA), and radius of gyration (Rg), demonstrating the rigid nature and inflexibility of the vaccine and receptor molecules. In addition, codon optimization, based on Escherichia coli K12, was used to determine the GC content and the codon adaptation index (CAI) value, which further followed for the incorporation into the cloning vector pET28+(a). Collectively, these findings suggested that the constructed vaccine could be used to modulate the immune reaction against SARS-CoV-2.

31 January 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
AOAhmad Jomah Obaidullah
Ahmad Jomah Obaidullah
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
NANawaf A. Alsaif
Nawaf A. Alsaif
AAAshwag S. Alanazi
Ashwag S. Alanazi
HAHussam Albassam
Hussam Albassam
Abu Montakim TareqAbu Montakim Tareq
Abu Montakim Tareq
The methanolic extract of Argyreia capitiformis stem was examined for anti-inflammatory activities following network pharmacology analysis and molecular docking study. Based on gas chromatography-mass spectrometry (GC-MS) analysis, 49 compounds were identified from the methanolic extract of A. capitiformis stem. A network pharmacology analysis was conducted against the identified compounds, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology analysis of biological processes and molecular functions were performed. Six proteins (IL1R1, IRAK4, MYD88, TIRAP, TLR4, and TRAF6) were identified from the KEGG pathway analysis and subjected to molecular docking study. Additionally, six best ligand efficiency compounds and positive control (aspirin) from each protein were evaluated for their stability using the molecular dynamics simulation study. Our study suggested that IL1R1, IRAK4, MYD88, TIRAP, TLR4, and TRAF6 proteins may be targeted by compounds in the methanolic extract of A. capitiformis stem to provide anti-inflammatory effects.

4 October 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
HAHussam Albassam
Hussam Albassam
Chetan MehtaChetan Mehta
Chetan Mehta
UNUsha Y Nayak
Usha Y Nayak
The endoplasmic reticulum (ER) is a cellular organelle responsible for the folding of proteins. When protein folding demand exceeds the folding capacity, cells trigger ER stress. ER-oxidoreductase 1α (ERO1α) is an ER stress component that controls oxidative folding protein. Upregulation of ERO1α was reported in distinct types of cancer including breast cancer and colon cancer. It was reported that deletion of ERO1 gene compromised cancer progression and cell proliferation in colon cancer. Thereby, ERO1α inhibition might be a clinically promising anti-cancer therapeutic target. In the present study, we conducted a virtual screening of 6,000 natural-product molecules obtained from Zinc database using a multistep docking approach with a crystal structure of human ERO1α. Our analyses from high throughput virtual screening revealed the top-ranked scores of 3000 molecules with glide scores of less than −4.0 kcal/mol. These molecules were further advanced to standard precision (SP) docking. The top 300 molecules of SP docking with glide scores ≤ −7.5 kcal/mol were chosen to undergo extra precision (XP) docking. Around 40 molecules that have conserved interactions with the binding site of ERO1α were ranked by the XP docking. Based on visual inspection, seven-candidate molecules that have high binding affinity scores and more molecular interactions were shortlisted. The dynamic stability of binding between the candidate molecules and ERO1α was characterized using 100 nanoseconds molecular dynamics simulation method. Two candidates exhibited strong and stable binding complexes with ERO1α. Collectively, these findings suggest that the identified molecules may serve as potential anti-cancer lead molecules subjected to further experimental validation. Communicated by Ramaswamy H. Sarma

24 February 2026 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
PDF file
HAHussam Albassam
Hussam Albassam
SASaad Alobid
Saad Alobid
FAFaris Almutairi
Faris Almutairi
FAFaisal Altowairqi
Faisal Altowairqi
Cancer remains a predominant cause of mortality worldwide, with conventional therapies often limited by adverse side effects and the development of drug resistance. Targeting receptor tyrosine kinases (RTKs), especially vascular endothelial growth factor receptor 2 (VEGFR2), presents a viable strategy due to its pivotal role in tumor angiogenesis. This study employed an integrative approach combining structure-based docking study, kinase inhibition assays, and cytotoxicity evaluations to identify novel VEGFR2 inhibitors. A Protein Kinase Diversity Set library comprising over 2,000 compounds was screened via molecular docking against the VEGFR2 crystal structure. The highest-ranking candidates were subjected to detailed binding interaction analyses. Cytotoxicity assays demonstrated significant anti-proliferative effects in VEGFR2-overexpressing U87 cells, while enzymatic assays confirmed one novel compound's potency in inhibiting VEGFR2 kinase activity. Redocking simulations focusing on the receptor's active site ensured comprehensive conformational exploration of ligand binding modes. Our results identify a promising lead compound as a novel inhibitor of VEGFR2, with potential applicability as an anti-angiogenic and anticancer therapeutic agent, warranting further optimization.

24 February 2025 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
HAHussam Albassam
Hussam Albassam
OAOmar Almutairi
Omar Almutairi
MAMajed Alnasser
Majed Alnasser
FAFaisal Altowairqi
Faisal Altowairqi
FAFaris Almutairi
Faris Almutairi
SASaad Alobid
Saad Alobid
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, driving an urgent need for effective therapies. A promising avenue of research focuses on the PI3K/AKT/mTOR signalling pathway, which is frequently disrupted by mutations in the PI3Kα subunit. Our cutting-edge study employed a structure-based virtual screening of ∼3000 compounds, leading to the discovery of F0608-0019, a highly potent and selective PI3Kα inhibitor. F0608-0019 demonstrated remarkable efficacy in suppressing HCT116 colorectal cancer cell proliferation, with an IC50 of 12.14 µM, while maintaining high selectivity by minimising activity against other PI3K isoforms. Advanced molecular dynamics simulations highlighted the stability of F0608-0019's binding interactions with key amino acids, such as TRP:780, ILE:932, and VAL:850, which are critical for its targeted action. These exciting findings reveal F0608-0019 as a leading candidate for innovative CRC therapies that selectively target PI3Kα dysregulation, offering promising new possibilities for effective CRC treatment.

9 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FAFaris Almutairi
Faris Almutairi
YAYazeed Alneef
Yazeed Alneef
HAHussam Albassam
Hussam Albassam
SASaad Ebrahim Alobid
Saad Ebrahim Alobid
AAAhlam Mohammed Alhusaini
Ahlam Mohammed Alhusaini
SASabry Mohamed Attia
Sabry Mohamed Attia
Background/Objectives: Lipid metabolism dysregulation contributes to cancer progression. Monoacylglycerol lipase (MAGL) breaks down 2-arachidonoylglycerol (2-AG) into glycerol and arachidonic acid, a substrate for cyclooxygenase-2 (COX-2) to produce pro-inflammatory mediators such as prostaglandin E2 (PGE2). Lipopolysaccharide (LPS) activation of Toll-like receptor 4 (TLR4) triggers inflammatory pathways, including COX-2/PGE2 signaling, implicated in diseases such as melanoma. MAGL inhibition reduces prostaglandins and other inflammatory mediators, but its role in inflammation-driven melanoma progression remains unexplored. This study investigated how JZL184, a selective MAGL inhibitor, and 2-AG affect LPS-induced inflammation, proliferation, and migration in B16 melanoma cells. Methods: Cells received LPS alone or with JZL184 or 2-AG. We measured inflammatory transcripts by qRT-PCR, COX-2 protein by Western blot, PGE2 release by ELISA, proliferation by CCK-8, and migration by scratch assay. Results: LPS increased COX-2, PGE2, VEGF, N-cadherin, and inflammatory cytokine expression. JZL184 suppressed these LPS-induced changes and reduced cell proliferation and migration. In contrast, 2-AG did not alter LPS-induced proliferation or inflammatory signals. JZL184’s effects on inflammatory gene expression and proliferation were independent of CB1 receptor signaling, suggesting its anti-melanoma activity may result from reduced inflammatory mediators rather than enhanced endocannabinoid signaling. Conclusions: These findings provide initial evidence that MAGL may regulate inflammation-triggered melanoma progression and could be a plausible therapeutic target.